EJPMR, 2026, 13(3), 549-554 **Review Article** **Impact Factor 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

IMMUNOMODULATORY ROLE OF BASTI KARMA THROUGH GALT IN THE MANAGEMENT OF ULCERATIVE COLITIS: A CONCEPTUAL AYURVEDIC REVIEW

***Dr. Shruthi S.**

Associate Professor In The Department of Panchakarma, Indian Institute of Ayurvedic Medicine and Research Bengaluru, Karnataka.

***Corresponding Author: Dr. Shruthi S.**

Associate Professor In The Department of Panchakarma, Indian Institute of Ayurvedic Medicine and Research Bengaluru, Karnataka.

DOI: https://doi.org/10.5281/zenodo.18937963

How to cite this Article: *Dr. Shruthi S. (2026). Immunomodulatory Role Of Basti Karma Through Galt In The Management Of Ulcerative Colitis: A Conceptual Ayurvedic Review. European Journal of Pharmaceutical and Medical Research, 13(3), 549–554.

Article Received on 15/02/2026 **Article Revised on 05/03/2026** **Article Published on 10/03/2026**

ABSTRACT

Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease characterized by continuous inflammation of the colonic mucosa, leading to symptoms such as bloody diarrhea, abdominal pain, tenesmus, and systemic manifestations. The disease arises from a complex interaction between genetic susceptibility, environmental factors, intestinal microbiota, and immune dysregulation. A crucial component of intestinal immune regulation is the gut-associated lymphoid tissue (GALT), which constitutes nearly 70% of the body's immune system and plays a fundamental role in maintaining mucosal immune homeostasis. In ulcerative colitis, abnormal activation of mucosal immune cells within GALT leads to excessive production of pro-inflammatory cytokines, disruption of epithelial barrier integrity, and chronic intestinal inflammation. Ayurveda describes gastrointestinal inflammatory disorders with clinical similarities to ulcerative colitis under disease entities such as **Grahani, Pittaja Atisara, and Raktatisara**, where impaired Agni (digestive metabolism), accumulation of Ama (metabolic toxins), and vitiation of Doshas—particularly Pitta and Vata—contribute to intestinal pathology. Among the Panchakarma procedures, **Basti Karma** is considered the most effective therapeutic modality for diseases originating in the **Pakvashaya (large intestine)**, which is regarded as the principal seat of Vata Dosha. Classical Ayurvedic texts describe Basti as "Ardha Chikitsa" (half of all therapeutic measures) due to its profound systemic effects and its ability to restore physiological balance. Recent biomedical insights suggest that rectally administered therapies can directly influence intestinal mucosal immunity through interactions with immune cells present in GALT. Basti formulations containing herbal decoctions, medicated oils, and bioactive phytoconstituents may exert anti-inflammatory, antioxidant, and immunomodulatory actions that help regulate cytokine activity, improve epithelial barrier function, and modulate gut microbiota. These mechanisms indicate a potential immunological basis for the therapeutic effects of Basti therapy in inflammatory bowel diseases. The present conceptual review aims to explore the **immunomodulatory role of Basti Karma through GALT in the management of ulcerative colitis**, integrating classical Ayurvedic principles with modern immunological understanding. This integrative approach may provide a theoretical framework for developing evidence-based Ayurvedic interventions for inflammatory bowel diseases and may open new avenues for translational research in integrative gastroenterology.

KEYWORDS: Ulcerative colitis, Basti karma, GALT, Ayurveda, Immunomodulation, Inflammatory bowel disease.

INTRODUCTION

Ulcerative colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract that primarily affects the mucosal layer of the colon and rectum. It belongs to the spectrum of inflammatory bowel diseases (IBD), which also includes Crohn's disease. The incidence and prevalence of ulcerative colitis have increased considerably over the past few decades, particularly in developing countries undergoing rapid urbanization and lifestyle changes. The disease typically presents with recurrent episodes of bloody diarrhea, abdominal discomfort, urgency, and rectal bleeding, significantly impairing the quality of life of affected individuals.[1]

From a biomedical perspective, the pathogenesis of ulcerative colitis involves a multifactorial interplay between genetic predisposition, environmental triggers, intestinal microbiota, epithelial barrier dysfunction, and immune dysregulation. One of the key components in maintaining intestinal immune homeostasis is the **gut-associated lymphoid tissue (GALT)**. GALT represents a specialized immune network consisting of Peyer's patches, isolated lymphoid follicles, lamina propria lymphocytes, intraepithelial lymphocytes, and mesenteric lymph nodes. These structures play a vital role in antigen recognition, immune tolerance, and defense against pathogenic microorganisms.[2]

In healthy individuals, GALT maintains a delicate balance between immune activation and immune tolerance toward commensal gut microbiota. However, in ulcerative colitis, this balance is disrupted, leading to exaggerated immune responses characterized by activation of T-helper cells, macrophages, and dendritic cells, along with the excessive release of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-17 (IL-17). This persistent inflammatory cascade damages the intestinal mucosa and perpetuates the disease process.[3]

Despite advances in pharmacological therapy, including corticosteroids, immunomodulators, and biological agents, the management of ulcerative colitis remains challenging due to frequent relapses, long-term medication dependency, and potential adverse effects. Consequently, there is increasing interest in complementary and integrative medical approaches that can provide safe and sustainable management strategies for inflammatory bowel diseases.[4]

Ayurveda, the traditional system of medicine in India, offers a comprehensive understanding of gastrointestinal disorders based on the principles of **Dosha, Agni, and Ama**. Although ulcerative colitis is not described as a single disease entity in classical Ayurvedic texts, its clinical manifestations closely resemble conditions such as **Pittaja Atisara, Raktatisara, and Grahani**. These conditions are characterized by impaired digestive fire (Mandagni), accumulation of toxic metabolic by-products (Ama), and vitiation of Doshas—particularly Pitta and Vata—leading to inflammation and dysfunction of the intestinal mucosa.[5]

Among the therapeutic procedures described in Ayurveda, **Basti Karma** occupies a central position in the management of diseases involving the colon and systemic disorders related to Vata Dosha. Basti involves the administration of medicated herbal decoctions, oils, or other formulations through the rectal route. Classical Ayurvedic texts emphasize that Basti therapy exerts systemic effects beyond the gastrointestinal tract due to its action on the **Pakvashaya**, which is considered a crucial physiological and pathological site in the body.[6]

AIMS AND OBJECTIVES

Aim

To explore the conceptual basis of immunomodulation through Basti Karma via gut-associated lymphoid tissue (GALT) in the management of ulcerative colitis.

Objectives

- To analyze the Ayurvedic understanding of ulcerative colitis in relation to Grahani, Pittaja Atisara, and Raktatisara.
- To review the structure and function of gut-associated lymphoid tissue in mucosal immunity.
- To examine the mechanism of action of Basti therapy in relation to intestinal immunity.
- To establish a conceptual link between Basti Karma and GALT-mediated immunomodulation.

MATERIALS AND METHODS

This study is a **conceptual review based on classical Ayurvedic literature and modern scientific sources**.

Ayurvedic Sources

- Charaka Samhita
- Sushruta Samhita
- Ashtanga Hridaya
- Commentaries and contemporary Ayurvedic textbooks

Modern Sources

- PubMed indexed journals.
- Research articles on mucosal immunity and inflammatory bowel disease.
- Studies related to rectal drug delivery and gut immunology.

  Keywords used for literature search included **ulcerative colitis, GALT, mucosal immunity, Basti therapy, Panchakarma, immunomodulation, and inflammatory bowel disease**.

Ulcerative Colitis: Biomedical Overview[7]

Pathophysiology

Ulcerative colitis involves chronic inflammation of the colonic mucosa characterized by.

- Disruption of epithelial barrier
- Dysbiosis of gut microbiota
- Activation of T lymphocytes
- Increased inflammatory cytokines (TNF-α, IL-6, IL-17)

Clinical Features

- Bloody diarrhea
- Tenesmus
- Abdominal pain
- Weight loss
- Fatigue

Immunological Mechanism

Component	Role in UC
T helper cells	Release inflammatory cytokines
Macrophages	Produce TNF-α and IL-1
Gut microbiota	Trigger immune activation
Intestinal epithelium	Barrier dysfunction

Ayurvedic Perspective of Ulcerative Colitis[8]

Ulcerative colitis closely resembles several conditions described in Ayurveda.

Ayurvedic Condition	Key Features	Correlation with UC
Pittaja Atisara	Bloody diarrhea, burning sensation	Mucosal inflammation
Raktatisara	Blood mixed stools	Rectal bleeding
Grahani	Chronic digestive disorder	Altered intestinal function

Samprapti (Pathogenesis)

- Mandagni (weak digestion)
- Formation of Ama
- Pitta aggravation
- Vata disturbance in Pakvashaya
- Damage to intestinal mucosa

Gut-Associated Lymphoid Tissue (GALT)[9]

GALT is a major component of mucosal immunity.

Components of GALT

Structure	Function
Peyer's patches	Antigen sampling
Lamina propria lymphocytes	Immune response
Intraepithelial lymphocytes	Barrier protection
Mesenteric lymph nodes	Immune regulation

Role in Immune Regulation

- Maintains tolerance to commensal bacteria
- Produces IgA antibodies
- Regulates inflammatory cytokines

In ulcerative colitis, GALT becomes hyperactive leading to chronic inflammation.

Basti Karma: Ayurvedic Perspective[10]

Basti therapy involves administration of medicated substances through the rectum to treat systemic and gastrointestinal disorders.

Types of Basti

Type	Description
Niruha Basti	Decoction-based cleansing enema
Anuvasana Basti	Oil-based nourishing enema
Matra Basti	Small dose oil enema

Therapeutic Effects

- Balances Vata Dosha
- Improves Agni
- Removes accumulated toxins
- Nourishes intestinal tissues

Immunomodulatory Role of Basti through GALT[11]

Basti therapy may exert immunomodulatory effects through several mechanisms.

1. Direct Interaction with Colonic Mucosa

Medicated Basti formulations directly contact the colonic mucosa, where GALT is abundant. Active phytochemicals may influence immune cells located within Peyer's patches and lamina propria.

2. Regulation of Cytokine Response

Herbal ingredients in Basti formulations often possess anti-inflammatory properties that may reduce cytokines such as TNF-α, IL-6, and IL-17.

3. Modulation of Gut Microbiota

Basti therapy may alter microbial composition, thereby reducing dysbiosis which is a key factor in UC pathogenesis.

4. Restoration of Intestinal Barrier

Medicated oils and herbal decoctions may help restore epithelial integrity and mucosal healing.

Conceptual Correlation between Basti and GALT

Ayurvedic Concept	Biomedical Interpretation
Pakvashaya as seat of Vata	Colon as immune-active organ
Basti therapy	Rectal drug delivery
Agni regulation	Metabolic and microbial balance
Dosha balance	Immune homeostasis

Table 1: Comparison between Ulcerative Colitis and Ayurvedic Disease Correlations.

Aspect	Ulcerative Colitis (Modern Medicine)	Ayurvedic Correlation
Disease nature	Chronic inflammatory bowel disease	Grahani / Pittaja Atisara / Raktatisara
Primary site	Colon and rectum	Pakvashaya
Pathogenesis	Immune dysregulation, epithelial damage, microbiota imbalance	Mandagni, Ama formation, Dosha vitiation
Major Dosha involved	—	Pitta and Vata predominance
Major pathology	Mucosal inflammation and ulceration	Dushthi of Annavaha and Purishavaha Srotas
Clinical features	Bloody diarrhea, abdominal pain, tenesmus	Atisara with Rakta, Grahani symptoms
Treatment approach	Anti-inflammatory drugs, immunosuppressants	Agni Deepana, Ama Pachana, Basti Karma

Table 2: Components of Gut-Associated Lymphoid Tissue (GALT) and Their Immunological Role.

GALT Component	Location	Immunological Function
Peyer's patches	Ileum and colon	Antigen sampling and immune activation
Isolated lymphoid follicles	Intestinal mucosa	Local immune surveillance
Lamina propria lymphocytes	Mucosal layer	Cytokine production and immune response
Intraepithelial lymphocytes	Intestinal epithelium	Maintain epithelial barrier
Mesenteric lymph nodes	Mesentery	Regulation of intestinal immune responses

Table 3: Types of Basti and Their Therapeutic Actions.

Type of Basti	Composition	Therapeutic Role
Niruha Basti (Asthapana)	Herbal decoction, honey, oil, salt	Detoxification, Dosha elimination
Anuvasana Basti	Medicated oils or ghee	Nourishment and Vata pacification
Matra Basti	Small dose medicated oil	Daily Vata balancing and tissue nourishment
Yapana Basti	Combination of nourishing and detoxifying drugs	Long-term disease management

Table 4: Proposed Mechanisms of Basti Karma in Ulcerative Colitis.

Mechanism	Possible Biomedical Interpretation
Vata pacification	Regulation of intestinal motility
Ama elimination	Reduction of inflammatory mediators
Pakvashaya action	Direct mucosal drug delivery
Rasayana effect	Tissue repair and immune modulation
Agni correction	Restoration of gut metabolism

Table 5: Ayurvedic Herbs Used in Basti with Immunomodulatory Properties.

Herb	Botanical Name	Pharmacological Activity
Guduchi	*Tinospora cordifolia*	Immunomodulatory, anti-inflammatory
Yashtimadhu	*Glycyrrhiza glabra*	Mucosal healing, anti-ulcer
Bala	*Sida cordifolia*	Anti-inflammatory, strengthening
Dashamoola	Polyherbal formulation	Anti-inflammatory and antioxidant
Musta	*Cyperus rotundus*	Digestive regulation and anti-diarrheal

Table 6: Conceptual Correlation between Basti Therapy and GALT-mediated Immunomodulation.

Ayurvedic Concept	Modern Immunological Interpretation
Pakvashaya as seat of Vata	Colon as major immune interface
Basti administration	Rectal drug delivery system
Dosha balance	Immune homeostasis
Agni restoration	Gut metabolic regulation
Rasayana effect	Immunomodulation and tissue repair

DISCUSSION

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by immune dysregulation, epithelial barrier damage, and altered gut microbiota. Contemporary biomedical research highlights that intestinal inflammation in ulcerative colitis is primarily mediated by dysregulated mucosal immunity involving gut-associated lymphoid tissue (GALT). The excessive activation of immune cells such as macrophages, dendritic cells, and T-helper lymphocytes leads to increased production of inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-17 (IL-17). These inflammatory mediators damage the intestinal mucosa, resulting in persistent inflammation, ulceration, and clinical symptoms such as bloody diarrhea and abdominal pain.[12]

Ayurveda provides a different yet complementary framework for understanding such gastrointestinal inflammatory disorders. The clinical features of ulcerative colitis resemble conditions described as **Pittaja Atisara, Raktatisara, and Grahani** in classical Ayurvedic texts. These disorders arise due to impairment of digestive fire (Mandagni), accumulation of Ama (toxic metabolic by-products), and vitiation of Doshas, particularly Pitta and Vata. When Agni becomes impaired, improperly digested food leads to the formation of Ama, which circulates through bodily channels and causes inflammatory reactions in the intestinal mucosa. The colon or Pakvashaya is considered the principal seat of Vata Dosha, and disturbance of Vata further aggravates intestinal motility and mucosal dysfunction.[13]

Basti Karma occupies a unique place in Ayurvedic therapeutics because it directly targets the Pakvashaya, the anatomical site corresponding to the large intestine. Classical Ayurvedic literature emphasizes that Basti therapy can regulate systemic physiology by correcting Vata Dosha and eliminating accumulated toxins. In the context of ulcerative colitis, Basti therapy may help restore intestinal homeostasis by correcting Dosha imbalance, improving Agni, and promoting mucosal healing.[14]

From a modern biomedical perspective, the rectal administration of medicated formulations enables direct interaction with the colonic mucosa where immune structures of GALT are highly concentrated. This provides a plausible explanation for the systemic and immunological effects described in classical Ayurvedic texts. The colon contains numerous immune cells such as lymphocytes, macrophages, and dendritic cells that participate in antigen recognition and immune regulation. When herbal formulations used in Basti come in contact with these immune structures, bioactive phytoconstituents may modulate immune responses through several mechanisms.[15]

One possible mechanism is the regulation of inflammatory cytokines. Many Ayurvedic herbs used in Basti preparations possess documented anti-inflammatory properties. For example, herbs such as Guduchi, Yashtimadhu, and Dashamoola have demonstrated the ability to inhibit pro-inflammatory cytokines and reduce oxidative stress. By reducing cytokine production within the intestinal mucosa, Basti therapy may help attenuate the chronic inflammatory cascade characteristic of ulcerative colitis.[16]

Another important mechanism involves restoration of the intestinal epithelial barrier. In ulcerative colitis, disruption of tight junctions in the epithelial lining increases intestinal permeability, allowing bacterial antigens to penetrate the mucosa and trigger immune responses. Medicated oils and herbal decoctions used in Basti therapy may exert protective effects on the intestinal mucosa by promoting epithelial repair and reducing mucosal inflammation. This may help restore barrier integrity and prevent further immune activation.

CONCLUSION

Ulcerative colitis is a chronic immune-mediated inflammatory disease of the colon in which dysregulation of mucosal immunity and gut microbiota plays a central role. Gut-associated lymphoid tissue forms the primary immune interface between intestinal microbes and the host immune system, and disturbances in this regulatory network contribute significantly to the pathogenesis of the disease. Ayurveda describes gastrointestinal inflammatory disorders with clinical similarity to ulcerative colitis under conditions such as Grahani, Pittaja Atisara, and Raktatisara. These conditions are primarily associated with impaired Agni, accumulation of Ama, and imbalance of Doshas, particularly Pitta and Vata. Basti Karma, being the principal therapy for disorders of the Pakvashaya and Vata imbalance, holds significant therapeutic potential in such conditions. From an integrative perspective, Basti therapy may exert immunomodulatory effects by interacting with immune components of the intestinal mucosa, particularly those associated with GALT. The herbal constituents present in Basti formulations may regulate inflammatory

cytokines, promote mucosal healing, restore epithelial barrier function, and modulate gut microbiota. These mechanisms collectively contribute to the restoration of intestinal immune homeostasis and reduction of chronic inflammation. Therefore, Basti Karma can be conceptually understood as an immunomodulatory therapy that influences mucosal immune regulation through the gut immune system. Integrating classical Ayurvedic knowledge with modern immunological understanding provides a valuable framework for exploring the therapeutic potential of Panchakarma procedures in inflammatory bowel diseases. Further experimental research and well-designed clinical trials are necessary to establish the immunological mechanisms and clinical efficacy of Basti therapy in ulcerative colitis. Such integrative investigations may contribute to the development of evidence-based Ayurvedic treatment protocols and expand the scope of complementary approaches in the management of chronic inflammatory gastrointestinal disorders.

REFERENCES

1. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. *Lancet*, 2012; 380(9853): 1606–19.
2. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. *Lancet*, 2017; 389(10080): 1756–70.
3. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature*, 2011; 474(7351): 307–17.
4. Podolsky DK. Inflammatory bowel disease. *N Engl J Med*, 2002; 347(6): 417–29.
5. Abraham C, Cho JH. Inflammatory bowel disease. *N Engl J Med*, 2009; 361(21): 2066–78.
6. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. *Nat Clin Pract Gastroenterol Hepatol*, 2006; 3(7): 390–407.
7. Neurath MF. Cytokines in inflammatory bowel disease. *Nat Rev Immunol*, 2014; 14(5): 329–42.
8. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature*, 2007; 448(7152): 427–34.
9. Danese S, Fiocchi C. Ulcerative colitis. *N Engl J Med*, 2011; 365(18): 1713–25.
10. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established therapies. *Lancet*, 2007; 369(9573): 1641–57.
11. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. *Nat Rev Immunol*, 2014; 14(3): 141–53.
12. Mowat AM, Agace WW. Regional specialization within the intestinal immune system. *Nat Rev Immunol*, 2014; 14(10): 667–85.
13. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science*, 2012; 336(6086): 1268–73.
14. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol*, 2009; 9(5): 313–23.
15. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell*, 2014; 157(1): 121–41.
16. Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases. *Gastroenterology*, 2017; 152(2): 327–39.